Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11636
Peer-review started: May 11, 2015
First decision: June 23, 2015
Revised: July 8, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: November 7, 2015
Core tip: The identification of blood-based biomarkers that could reliably detect the presence of early-stage gastric cancer or provide means to monitor the tumor dynamics is an unmet clinical need. Recently, considerable effort has been devoted to discovering various types of cancer-associated molecules in the blood of gastric cancer patients, and this has resulted in establishing biomarker models with remarkably high sensitivity and specificity. However, a validation in large-scale studies and a head-to-head comparison of the biomarker models and technologies are required before these biomarkers can be used in routine clinical practice.